Publisher Correction: CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides

Present address: Department of Safety Assessment, Genentech, Inc., San Francisco, CA, USA

Present address: Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

These authors contributed equally and are listed alphabetically: Sooraj Achar, François X. P. Bourassa, John Davies.

留言 (0)

沒有登入
gif